Key result
Percutaneous acute mechanical circulatory support rapidly stabilizes acute right ventricular failure and cardiogenic shock.
Why the study?
Right ventricular failure remains a major cause of morbidity and mortality, and the growing role of percutaneous acute mechanical circulatory support devices depends on improved algorithms for identifying RV failure, patient monitoring, and weaning protocols.
This review summarizes the pathophysiology of acute right ventricular failure and evaluates the mechanisms of action, clinical utility, and management strategies (including patient monitoring and weaning protocols) for percutaneous RV acute mechanical circulatory support devices.
Answers are grounded in this paper and cite their sources.
Supports early percutaneous RV support in acute failure with shock; extends device algorithms while leaving quantitative outcomes open.
Right ventricular (RV) failure remains a major cause of global morbidity and mortality for patients with advanced heart failure, pulmonary hypertension, or acute myocardial infarction and after major cardiac surgery. Over the past 2 decades, percutaneously delivered acute mechanical circulatory support pumps specifically designed to support RV failure have been introduced into clinical practice. RV acute mechanical circulatory support now represents an important step in the management of RV failure and provides an opportunity to rapidly stabilize patients with cardiogenic shock involving the RV. As experience with RV devices grows, their role as mechanical therapies for RV failure will depend less on the technical ability to place the device and more on improved algorithms for identifying RV failure, patient monitoring, and weaning protocols for both isolated RV failure and biventricular failure. In this review, we discuss the pathophysiology of acute RV failure and both the mechanism of action and clinical data exploring the utility of existing RV acute mechanical circulatory support devices.
No takes yet. Share an insight, caveat, or question.
Kapur et al. (2017) conducted a review in Acute right ventricular failure. Percutaneous acute mechanical circulatory support devices was evaluated. Percutaneous acute mechanical circulatory support devices rapidly stabilize patients with acute right ventricular failure and cardiogenic shock, though no quantitative trial results are reported.
Synapse has enriched 10 related papers. Consider them for comparative context: